Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Staar Surgical ( (STAA) ) has provided an update.
On January 15, 2026, STAAR Surgical Company’s board elected Neal C. Bradsher, founder and president of Broadwood Capital, Inc., as Board Chair and restructured the leadership and composition of its three standing committees—Audit, Compensation, and Nominating and Governance—so that each is now chaired and populated by directors the board has determined to be independent under NASDAQ rules, restoring the company’s compliance with NASDAQ’s Audit Committee independence requirements and ending its cure period. On the same date, the board created two new committees: a Search Committee tasked with guiding leadership decisions, including the process to identify a successor to the Chief Executive Officer, and an Insight and Engagement Committee designed to strengthen interaction with management, stakeholders and industry experts, with board members, including the new chair, eligible for additional compensation for these expanded governance responsibilities under the existing non-employee director compensation program.
The most recent analyst rating on (STAA) stock is a Sell with a $13.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
The score is primarily held down by poor financial performance (large losses and negative cash flow) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support due to a negative P/E and no dividend yield, and recent corporate events add uncertainty after the merger was rejected and terminated.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company operates in the medical device industry, specializing in implantable lenses and related ophthalmic products for vision correction, serving patients, surgeons and eye-care providers in global refractive surgery markets.
Average Trading Volume: 1,322,687
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.09B
Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.